Literature DB >> 15209152

13C-breath tests in the study of mitochondrial liver function.

M Candelli1, I A Cazzato, M A Zocco, E C Nista, L Fini, A Armuzzi, V Camise, M Santoro, L Miele, A Grieco, G Gasbarrini, A Gasbarrini.   

Abstract

Breath tests for "dynamic" liver function evaluation have been proposed several years ago. A variety of carbon-labelled breath tests for the assessment of mitochondrial, microsomal and cytosolic liver function have been described with the aim to increase data on liver disease staging, prognosis, and response to therapy. In the last years a great interest is developed about the use of breath test for liver mitochondrial function evaluation since it results impaired in a wide range of liver diseases either of genetic or acquired origin. In these cases mitochondrial oxidative metabolism of some substrates, as far as recovery of the hepatic energy state after a metabolic insult, results impaired because of the disfunction of the electron transport chain and/or ATP synthesis. Ketoisocaproic acid and methionine are the best studied carbon-labelled substrates for the investigation of mitochondrial functional damages related to structural alterations that occur in many liver diseases. Although these tests are simple, cost-effective and safe, to date there is still not general approval for their usefulness in clinical settings since they should fulfill several requirements to overcome the drawbacks of traditional quantitative tests. On the other hand, this field is relatively young and further studies are needed in order to assess the suitable substrate for the evaluation of the complex mitochondrial metabolism both in healthy subjects and in patients with liver disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15209152

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

1.  [13C]Methionine breath test to assess intestinal failure-associated liver disease.

Authors:  Debora Duro; Shimae Fitzgibbons; Clarissa Valim; Chi-Fu Jeffrey Yang; David Zurakowski; Melanie Dolan; Lori Bechard; Yong Ming Yu; Christopher Duggan; Tom Jaksic
Journal:  Pediatr Res       Date:  2010-10       Impact factor: 3.756

Review 2.  Clinical utility of 13C-liver-function breath tests for assessment of hepatic function.

Authors:  P Afolabi; M Wright; S A Wootton; A A Jackson
Journal:  Dig Dis Sci       Date:  2012-08-17       Impact factor: 3.199

3.  Diagnostic value of the C methacetin breath test in various stages of chronic liver disease.

Authors:  Hamizah Razlan; Nurhayaty Muhamad Marzuki; Mei-Ling Sharon Tai; Azhar-Shah Shamsul; Tze-Zen Ong; Sanjiv Mahadeva
Journal:  Gastroenterol Res Pract       Date:  2011-06-07       Impact factor: 2.260

Review 4.  (13)CO2 breath tests in non-invasive hepatological diagnosis.

Authors:  Joanna Musialik; Krzysztof Jonderko; Anna Kasicka-Jonderko; Magdalena Buschhaus
Journal:  Prz Gastroenterol       Date:  2015-01-14

5.  Effects of ergot alkaloids on liver function of piglets as evaluated by the (13)C-methacetin and (13)C-α-ketoisocaproic acid breath test.

Authors:  Sven Dänicke; Sonja Diers
Journal:  Toxins (Basel)       Date:  2013-01-15       Impact factor: 4.546

6.  Evaluation of quantitative liver function tests in HIV-positive patients under anti-retroviral therapy.

Authors:  M Miller; A Kahraman; B Ross; M Beste; Guido Gerken
Journal:  Eur J Med Res       Date:  2009-09-01       Impact factor: 2.175

7.  Hepatobiliary MRI: Signal intensity based assessment of liver function correlated to 13C-Methacetin breath test.

Authors:  Michael Haimerl; Ute Probst; Stefanie Poelsterl; Lukas Beyer; Claudia Fellner; Michael Selgrad; Matthias Hornung; Christian Stroszczynski; Philipp Wiggermann
Journal:  Sci Rep       Date:  2018-06-13       Impact factor: 4.379

8.  Validation of a new prognostic model to predict short and medium-term survival in patients with liver cirrhosis.

Authors:  Tomasz Dziodzio; Robert Öllinger; Wenzel Schöning; Antonia Rothkäppel; Radoslav Nikolov; Andrzej Juraszek; Paul V Ritschl; Martin Stockmann; Johann Pratschke; Maximilian Jara
Journal:  BMC Gastroenterol       Date:  2020-08-12       Impact factor: 3.067

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.